| Stage | IOSP | % of rev | SOLS | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $474M | 100.00% | $1.0B | 100.00% | SOLS ×2.21 |
| Gross profit | $129M | 27.26% | $345M | 32.98% | SOLS +5.7pp |
| Operating income | $42M | 8.80% | $164M | 15.68% | SOLS +6.9pp |
| Pre-tax income | $43M | 8.99% | $112M | 10.71% | SOLS +1.7pp |
| Net income | $32M | 6.67% | $88M | 8.41% | SOLS +1.7pp |
| Stage | IOSP | SOLS | Gap · A − B |
|---|---|---|---|
| Revenue | $474M100.00% | $1.0B100.00% | SOLS ×2.21 |
| Gross profit | 27.26%$129M | 32.98%$345M | SOLS +5.7pp |
| Operating income | 8.80%$42M | 15.68%$164M | SOLS +6.9pp |
| Pre-tax income | 8.99%$43M | 10.71%$112M | SOLS +1.7pp |
| Net income |
| 6.67%$32M |
| 8.41%$88M |
| SOLS +1.7pp |
None
No disclosed counterparties: IOSP.